David McIntosh: The Evolving Safety Framework for Plasma-Derived Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Plasma Protein Therapeutics Association’s post on LinkedIn:
“This interesting piece of work will be of significant interest to anyone working in, or interested in, this field of life-saving medicines.
A footnote to add is that what is being described is the 80 percent of current World supplies of plasma that are achieved via Voluntary Reasonably Compensated Donation (VRCD).
Plasma obtained via so-called ‘Unpaid Donation’ almost certainly generates similar results, but as there is so much less of it in the World, relevant data is more scarce.
What is certainly clear, from the vast body of evidence gathered throughout the years of this Century, is that VRCD plasma collection is as safe as, if not safer than, unpaid donor plasma.
As safe – and much more of it – is surely a winning formula!”
Plasma Protein Therapeutics Association (PPTA) shared a post on LinkedIn about a recent article by Halide Tuna et al, published in Annals of Blood, adding:
“A new peer-reviewed publication authored by PPTA’s Halide Tuna and Dr. Toby Simon explores how plasma-derived medicinal products have achieved today’s strong safety profile.
The publication in Annals of Blood highlights the evolution of the ‘safety tripod’ — donor screening, testing, and pathogen reduction — and its role in ensuring the continued safety of plasma-derived therapies.
The conclusion is clear: strong, science-driven systems continue to protect patients today, while ongoing surveillance, periodic evaluation of methods, and technological innovations are essential for future preparedness.”
Title: Plasma-derived medicinal products: a narrative review of the multi-layered approach to ensuring pathogen safety
Authors: Halide Tuna, Toby Simon
Other posts featuring David McIntosh on Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials